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AutophagyKetogenic amino acid (KAA) replacement diet has been shown to cure hepatic steatosis, a serious liver dis-
ease associated with diverse metabolic defects. In this study, we investigated the effects of KAA replacement
diet on nutrition sensing signaling pathway and analyzed whether induction of hepatic autophagy was in-
volved. Mice are fed with high fat diet (HFD) or KAA replacement in high-fat diet (30% fat in food; HFD)-fed
(HFDKAAR) and sacriﬁced at 8, 12, 16 weeks after initiation of experimental food. Hepatic autophagy was an-
alyzed in protein expression of several autophagy-associated molecules and in light chain-3 green ﬂuores-
cent protein (LC-3 GFP) transgenic mice. HFDKAAR showed increased AMP-activated protein kinase (AMPK)
phosphorylation and enhanced liver kinase B1 (LKB1) expression compared to control HFD-fed mice. The
KAA-HFD-induced activation of AMPK was associated with an increased protein expression of sirtuin 1
(Sirt1), decreased forkhead box protein O3a (Foxo3a) level, and suppression of mammalian target of
rapamycin (mTOR) phosphorylation compared with the HFD-fed mice. The intervention study revealed
that a KAA-replacement diet also ameliorated all the established metabolic and autophagy defects in the
HFD-fed mice, suggesting that a KAA-replacement diet can be used therapeutically in established diseases.
These results indicate that KAA replacement in food could be a novel strategy to combat hepatic steatosis
and metabolic abnormalities likely involvement of an induction of autophagy.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Hepatic steatosis is associated with serious metabolic disorders,
such as obesity, metabolic syndrome, dyslipidemia, and type 2 diabetes.
Non-alcoholic fatty liver disease, also known as non-alcoholic steato-
hepatitis, is a highly studied hepatic disease research topic [1–3]. There-
fore, knowledge of the precise pathomechanisms in these liver diseases
is essential, and molecular pathway-based therapeutic strategies have
emerged as important tools to combat these devastating diseases.
Autophagy is the system that maintains cellular homeostasis by
degrading and recycling unnecessary, aged, damaged or dysfunctional
components within cells [4]. The targets of autophagy are long-livedh fat diet; LC-3, light chain-3;
ctivated protein kinase; mTOR,
obox type O; Atg, autophagy-
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rights reserved.proteins and malfunctioning organelles [4]. Originally, autophagy was
observed as an energy-utilizing strategy in starvation or when the
amount of food was insufﬁcient to maintain body homeostasis [4].
However, the importance of autophagy is not limited to starvation
conditions. Defects in the autophagy system have been associated
with diseases, such as cancer [5], neurodegenerative diseases, including
Alzheimer's disease and Huntington's disease [6,7], atherosclerosis [8],
and age-relatedmacular degeneration [9]. Enhanced autophagy in calo-
rie restriction has been reported as an effective nutritional intervention
under pathological conditions [10–13], suggesting that autophagy could
play an essential role in tissue homeostasis. Furthermore, autophagy
has been reported to be essential in the protection from alcohol- and
non-alcohol-mediated liver injury [14,15]. Therefore, autophagy nor-
malization is likely a potent therapeutic strategy for hepatic diseases;
however, except for severe calorie restriction, no established tool has
reported inducing autophagy for disease intervention.
Food containing ketogenic essential amino acids (KAAs), which in-
clude high ratios of branched-chain essential amino acids, has been
shown to be beneﬁcial for metabolic abnormalities in humans [16]
and rodents [17–19]. However, contradictory data has been reported
showing negative correlations between ketogenic amino acids and
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synthesis pathways, together with increased oxygen consumption
and respiratory quotient, prevented hepatic steatosis [23]. In this
study, we analyzed the involvement of autophagy induction in the
high KAA diet-associated alteration of nutritional sensing pathways.
2. Materials and methods
2.1. Antibodies
LKB1, p-AMPK, AMPK, p-mTOR, mTOR, and Foxo3a antibodies
were obtained from Cell Signaling Technology (Danvers, MA).
β-Actin, LC3, Atg7, Atg13, and beclin antibodies were obtained from
Sigma (St. Louis, MO), and the anti-P62/SQSTM1 antibody was pur-
chased from MBL (Nagoya, Japan).
2.2. Diets
For the C57/Bl6 mouse experiments, the control diet (control),
high-fat diet (HFD) and KAA-fortiﬁed HFD (HFDKAAR) were prepared
based on our previous report [23]. The casein-mimic free amino acid
mixture (CAAM) or KAA mixture was used to replace a portion of
the protein component. Using partial protein replacement by free
KAA, the essential/non-essential amino acids (E/N) ratio in the diet
was 1.8. Additionally, to avoid changes in the amounts of dietary
total amino acids, fat and carbohydrates, the total amino acids, in-
cluding protein/amino acids, were equalized among the groups by
the addition of up to 23% of CAAM (Supplementary Table 1).
2.3. Animals
All studies were reviewed and approved by the Institutional Animal
Care Committee of Kanazawa Medical University. Eight-week-old male
C57/Bl6 mice were obtained from CLEA Japan, Inc. (Tokyo, Japan). All
mice were housed in colony cages and maintained on a 12:12-hour
light and dark cycle with free access to water. Male LC3-GFP mice
(C57/Bl6 background) were obtained from Riken Bio Resource Center
(Ibaraki, Japan). Mice were fed a control diet, HFD or HFDKAAR from
the age of 8 weeks. The metabolic status and histological/biochemical
evaluations were performed at 8, 12 or 16 weeks after the initiation of
the indicated diets. For the interventional protocol, mice were fed an
HFD for 8 weeks. Then, 8 weeks after HFD initiation, the HFD-fed
mice were divided into two groups: one group of mice was fed the
same HFD, and the other group was fed HFDKAAR for 4 or 8 weeks.
2.4. Glucose tolerance
Mice were starved for 6 h before the injection of glucose (1 g/kg
BW) intraperitoneally (intraperitoneal glucose tolerance test: IPGTT).
Blood glucose levels were measured at 0, 15, 30, 60, 90 and 120 min
after the injection of glucose. In the 12-week protocol, we measured
insulin levels via an ELISA (Morinaga Institute of Biological Science,
Inc.). The insulin resistance index (IRI) was calculated by a previously
reported method (IRI = glucose (mmol/L) × insulin (mU/L)/22.5)
[24]. The levels of ketone bodies in the plasma were evaluated by an
ELISA (Bioassay System, Hayward, CA).
2.5. Oil Red O staining
Frozen liver sections were used for the evaluation of hepatic
steatosis, and Oil Red O staining was performed. 8-μm fresh frozen
liver sections were ﬁxed in 10% formalin for 15 min, rinsed in distilled
water, and placed in 60% isopropylene for 1 min. They were then
stained in an Oil Red O solution (0.5 g of Oil Red O dissolved in
100 mL of isopropylene) for 20 min at 37 °C, placed in 60%
isopropylene for 1 min, washed with distilled water three times,and mounted with 70% glycerin jelly. The red lipid droplets were ob-
served using microscopy.
2.6. LC3-GFP detection
Mice were anesthetized by procaine and perfused with a ﬁxative
(4% paraformaldehyde in PBS). Fixed samples were then stored at
−80 °C until evaluation. Frozen sections (5 μm) were observed by
microscopy to detect LC3-positive puncta. LC3-GFP-positive cells,
which were observed in 200× visual ﬁelds, and then counted and
quantiﬁed.
2.7. Macrophage detection
Five-micrometer sections of frozen liver samples were used for
macrophage labeling by F4/80. Samples were ﬁxed with −20° ace-
tone for 10 min; after blocking with PBS containing 2% BSA, the sec-
tions were incubated with an anti-F4/80 antibody (AbD Serotec,
Oxford, UK) in PBS containing 2% BSA for 1 h. The sections were
washed three times and incubated with a TRITC-conjugated second-
ary antibody (1:200 dilution; Jackson ImmunoResearch, West
Grove, PA) at room temperature for 30 min. After washing three
times and mounting, which included DAPI staining (Vector Laborato-
ries, Inc. Burlingame, CA), the F4/80-positive macrophages were visu-
alized by ﬂuorescence microscopy (Biozero, Keyence, Osaka, Japan).
The number of F4/80 positive macrophages per ﬁeld of view (×400
magniﬁcation) was assessed by counting positively labeled cells in 5
random ﬁelds of view per slide, with 5 slides per experimental
group. The results were evaluated by two independent investigators.
2.8. Western blotting
All the tissue samples were harvested without starvation. Protein
lysates were boiled in sample buffer containing sodium dodecyl sul-
fate (SDS) at 100 °C for 5 min. After centrifugation at 17,000 ×g for
10 min at 4 °C, the supernatant was separated on 6% or 12% SDS-
polyacrylamide gels and blotted onto PVDF membranes (Immobilon,
Bedford, MA) with a semidry method. After blocking with TBS-T
(Tris-buffered saline containing 0.05% Tween 20) containing 5%
non-fat dry milk or bovine serum albumin (BSA), the membranes
were incubated with each primary antibody in TBST containing 5%
BSA at 4 °C overnight. The membranes were washed three times
and incubated with a 1:2000 dilution of horseradish peroxide
(HRP)-conjugated secondary antibody (Cell Signaling Technology)
at room temperature for 1 h. The immunoreactive bands were
detected with an enhanced chemiluminescence (ECL) detection
system (Pierce Biotechnology, Rockford, IL).
2.9. Statistical analysis
The data are expressed as the mean ± s.e.m. in a graph. The Mann–
Whitney U-test was used to detect statistical signiﬁcance (deﬁned as
P b 0.05). GraphPad Prism 5.0 was used for statistical analysis.
3. Results
3.1. The effect of KAA replacement diet on weight of body and organs
Whenused for 8 weeks, a KAA replacement diet has been shown to
ameliorate high fat diet-induced obesity, glucose intolerance, and
lipotoxicity in mice [23]. In our study, we ﬁrst proposed the use of a
longer treatment, such as 12 or 16 weeks, of a KAA diet. When the
body weights of the mice were analyzed, all groups of mice exhibited
similar bodyweights, even in the HFD-fed groups, until 12 weeks after
the induction of nutritional intervention (Fig. 1A). The HFD-fed group
of mice displayed signiﬁcantly heavier body weight at 16 weeks after
Fig. 1. Body and organ weights and food intake of the mice. A. Time course of body weight changes in the mice. Eight-week-old C57/Bl6 mice were fed the indicated diets (0 W on
the graph). The body weight of each mouse was evaluated each week, and the averages are plotted. B. The body weights of the mice at the indicated weeks after the indicated diet
was initiated: 8 W (control n = 10, HFD n = 8, HFDKAAR n = 10), 12 W (control n = 12, HFD n = 11, HFDKAAR n = 12, HFD → HFDKAAR n = 12), and 16 W (control n = 4, HFD
n = 4, HFDKAAR n = 5, HFD → HFDKAAR n = 5). C. The liver, kidney, epididymal fat and heart weights: 8 W (control n = 4, HFD n = 5, HFDKAAR n = 5), 12 W (control n = 8, HFD
n = 7, HFDKAAR n = 7, HFD → HFDKAAR n = 7), and 16 W (control n = 4, HFD n = 4, HFDKAAR n = 5, HFD → HFDKAAR n = 5). D, E. 3–4 mice are housed in the cage. The food
intake was evaluated each week, and the average level per mouse was analyzed for each indicated group after the initiation of the protocol. The food intakes at 8 and12 weeks after
experimental food initiation were not analyzed due to IPGTT, which may affect the amount of food taken. The number of mice analyzed was the same as shown in B. Data are
expressed as the mean + s.e.m.
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cal calories, nitrogen content and fat, the KAA replacement diet
(HFDKAAR)-fed mice weighed less compared to the HFD-fed group of
mice (Fig. 1A, B). We evaluated the weight of several organs. The
liver weights were the same in all of the groups until 12 weeks after
the induction of nutritional treatment (Fig. 1C). Sixteen weeks after
protocol initiation, the livers of HFD-fed mice displayed heavier
trend when compared to the livers of control diet-fed mice, whereas
livers from mice fed the HFDKAAR diet were signiﬁcantly lighter com-
pared to the HFD-fed mice (Fig. 1C). The kidney weights were slightly
but signiﬁcantly heavier in HFD-fedmice compared to control diet-fed
mice at 16 weeks after the initiation of the experimental protocol
(Fig. 1C). The epididymal fat weight was heavier in the HFD-fed
mice compared with the control diet-fed mice in the time period ana-
lyzed, and the HFDKAAR-fed mice exhibited a signiﬁcantly lower epi-
didymal fat weight compared with the HFD-fed mice (Fig. 1C). The
heart weight remained constant in all groups of mice during the ex-
perimental protocol (Fig. 1C). An analysis of the daily food intake indi-
cated that the mice did not prefer to eat food containing high fat
compared with normal chow and that the HFDKAAR diet did not affect
the food intake until 12 weeks after initiation of experimental food
initiated (Fig. 1D). After 12 weeks, mice in HFD group started to eat
more foods when compared to HFDKAAR (Fig. 1D). Per calorie-based
analysis revealed that all groups of mice ate almost identical calories
until 12 weeks after the protocol (Fig. 1E). Similar to the food amount
data, mice in HFD group took more calories when compared to other
groups from 12 weeks after protocol initiation (Fig. 1E).
3.2. KAA replacement diet inhibit HFD-induced glucose tolerance defects
The effect of a KAA replacement diet on glucose metabolism was
analyzed by IPGTT. The HFD-fed mice exhibited a signiﬁcant deterio-
ration of glucose tolerance at 12 and 16 weeks after the initiation ofthe experimental protocol (Fig. 2A–C) in addition to higher insulin
levels (Fig. 2D, E). The HFDKAAR-fed mice exhibited signiﬁcantly ame-
liorated glucose tolerance compared to the HFD-fed mice (Fig. 2A–C),
as similar to the observation we reported [23]. This amelioration of
glucose tolerance by the KAA diet was associated with decreased in-
sulin levels (Fig. 2D, E). When IRI was analyzed using previously
reported formula during IPGTT [24] it demonstrated that the HFDKAAR
diet signiﬁcantly ameliorated IRI compared to the HFD-fed mice
(Fig. 2F).3.3. KAA replacement diet prevent HFD-induced hepatosteatosis
Upon analysis with Oil Red O staining, we found that both 12 and
16 weeks of treatment with the KAA-containing diet signiﬁcantly
ameliorated hepatic steatosis in mice (Fig. 3A–E). Twelve weeks of
treatment with HFD suppressed LKB1 expression, which was associ-
ated with decreased AMP-activated protein kinase (AMPK) phos-
phorylation (Fig. 3F, G). In contrast, treatment with the HFDKAAR
diet increased LKB1 expression, which was associated with increased
levels of AMPK phosphorylation compared to the HFD-fed mice
(Fig. 3F, G). The HFD-fed mice were also observed to have suppressed
levels of the sirt1 protein, whereas the KAA diet increased the expres-
sion levels of sirt1 (Fig. 3F, G). Mammalian target of rapamycin
(mTOR) levels and their phosphorylation levels were not signiﬁcantly
altered in mice fed the HFD in our analysis compared to the control
diet-fed mice, although the KAA-containing diet signiﬁcantly
suppressed mTOR phosphorylation levels (Fig. 3F, G). The analysis
of the effect of the KAA diet on forkhead box protein O3a (Foxo3a)
levels revealed similar trends to those observed for mTOR (Fig. 3F,
G). Mice treated for 16 weeks with an HFD displayed similar molecu-
lar defects in the livers when compared to 12 weeks of treatment and
HFDKAAR diet rescued such molecular defects (data not shown).
Fig. 2.Metabolic characteristic of mice. A–C. An intraperitoneal glucose tolerance test (IPGTT) at the indicated weeks after initiation of the experimental protocol. Mice were starved
for 6 h starting at 8:30 AM, and subsequently, glucose (1 g/kg BW) was intraperitoneally injected. Blood glucose levels were monitored at the indicated times after glucose injection
(n = 4 for each group). D. The insulin levels at the indicated time points during IPGTT. E. Area under the curve for insulin levels was analyzed in indicated groups. F. Insulin resis-
tance indexes were evaluated as previously reported [24]. Data are expressed as the mean + s.e.m.
1608 L. Xu et al. / Biochimica et Biophysica Acta 1832 (2013) 1605–16123.4. Liver autophagy induction by KAA replacement diet
A deﬁciency in autophagy has been implicated in metabolic
defects in several organs, such as the liver, heart, kidney and muscles
[4]. Upon analysis of GFP-LC3 mice, in which LC3-positive puncta
formation can be visualized with ﬂuorescence microscopy [25], the
control diet-fed mice exhibited GFP-positive LC3-positive punctaFig. 3. Hepatic steatosis and nutrition-induced signal transduction in the liver. A–E. Oil Red
diet, high-fat diet (HFD) or HFD with ketogenic amino acids (HFDKAAR). Representative ima
F–G. The effects of the KAA diet on the nutrition-sensing pathway in the livers of the indicate
shown. G. Densitometric analysis of each protein expression normalized as indicated in ﬁgformation in the liver (Fig. 4A) after 48 h of starvation. In contrast,
the livers of HFD-fed mice displayed a signiﬁcant suppression of
LC3-positive puncta formation after 8 weeks of treatment with this
diet (Fig. 4A, B), even with starvation. The HFDKAAR diet-fed mice
exhibited enhanced LC3-positive puncta formation compared to the
HFD-fed mice (Fig. 4B, C). Similarly, the KAA replacement diet-fed
mice exhibited increased LC3-positive puncta formation in the liverO staining in the liver tissue. C57/Bl6 wild-type mice (8 weeks old) were fed a control
ges (200×) are presented in the ﬁgure. At least four mice were analyzed in each group.
d groups of mice at 12 W (F) are shown. Representative data (n = 2) in each group are
ure. Data are shown as the mean ± s.e.m. in a graph (n = 4).
Fig. 4. KAA diet-induced autophagy in liver. A–E. LC3-GFP transgenic mice were fed a control diet, HFD or HFDKAAR. Mice were euthanized at 8 or 12 weeks after the induction of the
experimental protocol. After 48 h of starvation, the mice were perfused with ﬁxative (4% paraformaldehyde in PBS) under general anesthesia, and the organs were harvested. After
a 6-hour incubation in ﬁxative, the ﬁxed samples were transferred to a 30% sucrose solution in PBS for 24 h. Subsequently, the samples were placed in OCT mounting media, and
frozen samples were sectioned at 5 μm. The sectioned samples were analyzed using ﬂuorescence microscopy. LC-3 positive puncta formations were visualized by LC3-GFP-positive
vacuoles (indicated by yellow arrowheads). F. Quantitative analysis of LC3-GFP-positive puncta formation in the liver. Liver sections (200×) were analyzed by ﬂuorescence micros-
copy, and LC3-GFP puncta were counted in the visual ﬁeld. In each group, 4 sections were analyzed. G. Autophagy-associated molecules analyzed by western blot analysis. C57/Bl6
wild type mice were used in this analysis. Representative data (n = 2) in each group are shown. H. Densitometric analysis of each protein expression normalized as indicated in
ﬁgure. Data are shown as the mean ± s.e.m. in the graph (n = 4).
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protocol (Fig. 4D, E, F). Livers of HFD-fed mice exhibited suppression
of LC3-II and mTOR target protein Atg13, a component of an autoph-
agy initiation factor, at 12 weeks (Fig. 4G, H). The ATG7, ATG9 and
beclin protein levels exhibited no signiﬁcant differences (Fig. 4G).
Molecular defects associated with the autophagy system were also
found in mice fed an HFD for 16 weeks (data not shown). The KAA
diet-fed mice did not show the autophagy-related molecular defects,
such as suppression of LC3-II and Atg13, observed in mice fed an HFD
for 12 weeks (Fig. 4G, H). p62 levels were not altered the levels by
HFD but KAA replacement diet decreased p62 levels in liver (Fig. 4G,
H). These analyses suggested KAA-enhanced out-ﬂux of autophagy.
3.5. KAA replacement diet inhibits HFD-inducedmacrophage accumulation
in liver
Hepatic steatosis has been shown to associate with macrophage
accumulation in the liver [26,27]. In our analysis, as expected, the
HFD-fed mice exhibited enhanced macrophage accumulation in the
liver compared to control diet-fed mice (Supplementary Fig. 1A, B,
D). This macrophage accumulation was restored to normal levels in
the KAA diet-fed mice (Supplementary Fig. 1B, C, D).
3.6. Intervention by KAA replacement diet cures established hepatosteatosis,
defects in metabolism and autophagy, and macrophage accumulation in
HFD-fed mice
Next, we investigated whether nutritional intervention with KAAs
could reverse the metabolic abnormalities in established liver
steatosis and glucose tolerance defects. After 8 weeks on an HFD
diet, the mice exhibited liver steatosis (Fig. 5A). At 8 weeks after
being fed the HFD, some of the mice were switched to an HFDKAAR
diet. A subsequent 8-week HFDKAAR intervention (16 weeks total on
HFD) resulted in mice that had a decreased body weight (Fig. 1A, B)
and decreased liver and epididymal fat weights (Fig. 1C) compared
to mice fed the HFD for 16 weeks. After 8 weeks of treatment with
the KAA diet, hepatic steatosis was almost completely reversedcompared to the established hepatic steatosis in mice fed an HFD
for 8 weeks (Fig. 5A, B). Compared to the livers of mice on an HFD
for 8 weeks, the KAA diet induced LKB1 and AMPK phosphorylation,
which was associated with sirt1 protein induction and Foxo3a protein
suppression, at both 4 and 8 weeks after treatment (Fig. 5C). These
alterations in nutritional sensing pathway are associated with molec-
ular defects of autophagy regulation, such as suppression of LC3-II,
Atg13 and the accumulation of p62 (Fig. 5D). The KAA-replaced diet
reversed the HFD-induced defects in nutritional-sensing and autophagy-
regulated molecules (Fig. 5C, D). The amelioration of hepatic steatosis
by a KAA-replacement diet was associated with some improvements
in HFD-impaired glucose intolerance after 4 and 8 weeks of treatment
with the KAA diet (Fig. 5E, F). Both insulin levels and IRI analysis
exhibited suppressed trend in HFDKAAR intervention group of mice
(Fig. 5G, H) After 8 weeks, the HFD-fed mice exhibited enhanced mac-
rophage accumulation in the liver (Supplementary Fig. 2A, D). Thismac-
rophage accumulation was decreased by the KAA-replacement diet
after 8 weeks of treatment (Supplementary Fig. 2A, B, C, D).
3.7. Ketone bodies were not altered by KAA replacement diet
Ketone body levels in the plasma were similar in all groups' anal-
ysis (Supplementary Fig. 3A). When analyzed by LC–MS/MS analysis,
ketone bodies such as β-hydroxybutylate (Supplementary Fig. 3B)
and acetoacetate (Supplementary Fig. 3C), were not altered in KAA
replacement diet, even though there was some trend of elevation in
β-hydroxybutylate (Supplementary Fig. 3B).
4. Discussion
4.1. Obesity associated metabolic defects emerge important topic in
medicine
The worldwide epidemic of obesity and associated metabolic
defects reveals serious health problems. Themedical costs for treating
complications due to metabolic defects are a serious economic prob-
lem. Although modiﬁcations in lifestyle together with appropriate
Fig. 5. The KAA diet reversed established hepatic steatosis andmetabolic defects associatedwith enhanced autophagy. A, B. C57/Bl6 wild typemice were fed anHFD for 8 weeks. Mice
were then switched to a, HFDKAAR diet. Oil Red O staining indicated that an 8-week intervention with the KAA diet reverses the lipid accumulation in the liver. C. Nutritional-sensing
pathways are ameliorated by a KAA diet. The KAA diet reversed the suppression of LKB1 and AMPK activity that was associated with sirt1 suppression and Foxo3a induction after
treatment with an HFD for 8 weeks. The effect of the KAAs is most likely time-dependent. D. Autophagy-associated molecules. The KAA diet increased the LC3-II and Atg13 levels
compared to mice treated with an HFD for 8 weeks. E, F. The effect of the KAA intervention on glucose tolerance. Mice treated with a high-fat diet for 8 weeks were divided into
HFD or HFDKAAR groups. At 4 or 8 weeks after the diet change to the KAA addition, IPGTT was performed again on the same mice. G. The insulin levels at the indicated time points
during IPGTT. The inset in panel (G): area under the curve for insulin levels was analyzed in indicated groups. H. Insulin resistance indexes were evaluated as previously reported
[24]. n = 4 or 5 in each group. Data are expressed as the mean + s.e.m.
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these metabolic defects, the strict control of these interventions
coupled with an appropriate evaluation is challenging. Interventions
for examining metabolic defects need to be easily performed and
compliant for continuation. Therefore, a KAA replacement diet with-
out alteration of total fat or calorie intake could be used to compare
either the reduction in total food amount or fat consumption,
suggesting the potential utility of KAA interventions for established
metabolic diseases.4.2. KAA diet is associated with amelioration of glucose tolerance in mice
A previous study revealed that branched-chain amino acids and
their metabolic byproducts were linked to insulin resistance in
humans and experimental animals [21]. In Newgard's seminal publi-
cation they compared the effect of HFD (kcal base: 45% fat, 35% carbo-
hydrate, and 19% protein) vs. HFD + BCAA (kcal base: 43% fat, 34%
carbohydrate, and 23% protein) in Wistar rats [21]; in our analysis
we used identical calorie based recipe in either HFD or HFDKAAR
(kcal base: 53% fat, 29% carbohydrate, and 19% protein) in mice
(Supplementary Table 2). We can ﬁnd several important differences
between Newgard's study and our current study. First of all,
Newgard's study demonstrated that the HFD diet fed Wistar rats
exhibited signiﬁcantly heavier in body weight, whereas in our current
study with C57/B6 mice we could not ﬁnd any differences in body
weight by HFD fed at least up to 12 weeks. These differences cannot
be simply explained by the amount of food intake because animals
ate about the similar calories between control and HFD fed in either
Newgard's study or our current study. Another important point was
that Newgard's study demonstrated the reduction of calorie intake
by BCAA supplementation; therefore they performed the pair-fed
study in which they again found BCAA-induced deterioration ofglucose tolerance [21]. In our study basically we could not ﬁnd any
differences in food intake in all groups of prevention studies and the
only tiny temporal reduction in food intake was found by HFDKAAR
in intervention study. Although the recipe of experimental food etc.
looking similar, such differences found in the studies indicated that
the experimental food of both studies did not induce the same meta-
bolic alteration in the rats and mice studied, and that as a conse-
quence of such differences, the biochemical and metabolic changes
induced by the KAA supplementation may have been different from
the ﬁnding by Newgard's work. It could be possible that the degree
of caloric and/or HFD intake is a fundamental factor in determining
the outcome of BCAA (or KAA) supplementation/replacement.
Regarding this ﬁnding, people with higher levels of branched-chain
amino acids in their blood are much more likely to develop diabetes
[20]. Gastric bypass surgery has been shown to decrease the levels of
total amino acids and branched-chain amino acids in association with
better glucose tolerance compared to dietary interventions in which the
amino acid levels never changed [22]. Recently, however, Theytaz et al.
reported that supplementation with essential amino acids blunts the
deteriorated metabolic proﬁling during fructose overfeeding in healthy
volunteers [28]. These reports are indeed contradictory to each other,
although the causal role of branched-chain amino acids in the onset of
insulin resistance remains elusive. Future research should be performed
to answer such important discrepancy by appropriate diet feeding design.4.3. Induction of autophagy associated with AMPK activation by KAA
Another important ﬁnding in our analysis was the amelioration of
HFD-mediated autophagy defects by a KAA-replacement diet. The
precise molecular mechanisms by which a KAA-replacement diet
enhanced hepatic autophagy are not yet clear; however, it is possible
that enhanced autophagy could induce degradation and a subsequent
1611L. Xu et al. / Biochimica et Biophysica Acta 1832 (2013) 1605–1612rearrangement of cellular systems that are rich in damaged and old cel-
lular components, thus potentially reducing harmful metabolic effects
on the maintenance of cellular homeostasis [4,29]. Autophagy has
been shown to be essential in liver protection against alcoholic or
non-alcoholic liver injury [14,15]. In our analysis, a KAA-replaced diet
increased the LKB1 levels and subsequent phosphorylation of AMPK,
which is a master regulator and sensor of cellular energy [30], even
with the HFD treatment. Enhanced AMPK activation and suppression
of mTOR have been shown to be associated with an induction of
autophagy [31,32] and organ protection [33–36]. Indeed Atg13, one of
the autophagy initiation factor and target of mTOR, was induced in
KAA diet, suggesting that a KAA diet can induce autophagy, normaliza-
tion of hepatic histology and restoration of metabolic disease states.
5. Conclusion
We conclude that a KAA replacement diet could be a potential
nutritional intervention for treatment in patients with metabolic
defects, such as hepatic steatosis, glucose intolerance and metabolic
syndrome, via a normalization of the nutritional signal responses
and associated autophagy defects. The effect of a KAA-replacement
diet can be conﬁrmed in mice with established metabolism defects.
Our analysis enables us to establish an evidence-based nutritional
intervention for patients with devastating metabolic defects, which
result in associated health problems worldwide.
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